Navigation Links
Research brings us nearer to understanding how neuro cells turn cancerous
Date:7/22/2014

Scientists from the Sloan-Kettering Institute for Cancer Research in New York with the help of Plymouth University Peninsula Schools of Medicine and Dentistry have completed research which for the first time brings us nearer to understanding how some cells in the brain and nervous system become cancerous.

The results of their study are published in the prestigious journal Cancer Cell.

The research team led by Sloan-Kettering researchers studied a tumour suppressor called Merlin.

The results of the study have identified a new mechanism whereby Merlin suppresses tumours, and that the mechanism operates within the nucleus. The research team has discovered that unsuppressed tumour cells increase via a core signalling system, the hippo pathway, and they have identified the route and method by which this signalling occurs.

By identifying the signalling system and understanding how, when present, Merlin suppresses it, the way is open for research into drug therapies which may suppress the signalling in a similar way to Merlin.

Tumour suppressors exist in cells to prevent abnormal cell division in our bodies. The loss Merlin leads to tumours in many cell types within our nervous systems. There are two copies of a tumour suppressor, one on each chromosome that we inherit from our parents. The loss of Merlin can be caused by random loss of both copies in a single cell, causing sporadic tumours, or by inheriting one abnormal copy and losing the second copy throughout our lifetime as is seen in the inherited condition of neurofibromatosis type 2 (NF2).

No effective therapy for these tumours exists, other than repeated invasive surgery aiming at a single tumour at a time and which is unlikely to eradicate the full extent of the tumours, or radiotherapy.

Professor Oliver Hanemann, Director of the Institute of Translational and Stratified Medicine at Plymouth University Peninsula Schools of Medicine and Dentistry, and who led the Plymouth aspect of the study, commented: "We have known for some time that the loss of the tumour suppressor Merlin resulted in the development of nervous system tumours, and we have come tantalisingly close to understanding how this occurs. Our joint study with colleagues at the Sloan-Kettering Institute for Cancer Research shows for the first time how this mechanism works. By understanding the mechanism, we can use this knowledge to develop effective drug therapies in some cases adapting existing drugs to treat patients for whom current therapies are limited and potentially devastating."


'/>"/>
Contact: Andrew Gould
andrew.gould@plymouth.ac.uk
University of Plymouth
Source:Eurekalert

Related medicine news :

1. Global Molecular Diagnostics Market Expected to Reach USD 8.7 Billion through 2019: Transparency Market Research
2. SkillSurvey to Present Research on Contingent Workers at National Association for Health Care Recruitment IMAGE 2014 Conference
3. Growth of Disposable Medical Supplies Market to 2019 Report Available at RnRMarketResearch.com
4. Hypatia Research Group Publishes “Enterprise Governance, Risk & Compliance: Best Practices, Maturity Models and 2014 ProductMatrix Vendor Evaluations”
5. Communication about female condom vital to young adults, UT Arlington researchers say
6. Chocolate Production in Canada Industry Market Research Report Now Available from IBISWorld
7. New research from Africa on pharmacomicrobiomics
8. Indoor Sports Facilities Management in the US Industry Market Research Report from IBISWorld Has Been Updated
9. Global and China Handpiece Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com
10. Benzoyl Peroxide Market Analysis for Global, China Regions – 2014 Development Trends Available at DeepResearchReports.com
11. Canadian Statistics May Help Prioritize Mesothelioma Research, According to Surviving Mesothelioma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on his ... the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his family ... hospital’s 30th heart transplant recipient. , “He was playing at home, when we got ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... One ... regular changing of the securement tape is painful for her. "This is why the ... to patients’ heads," she said. , They then created a prototype of the patent-pending ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic and ... website, which launched October 17, 2016, features comprehensive information regarding a wide range ... Visitors and patients can discover the latest clinical dermatology treatments for medical skin ...
(Date:12/7/2016)... ... , ... The medical profession is well aware that heart attacks do indeed ... heart attacks among 138,602 people recorded a 35% higher number of heart attacks in ... of course–no time of year is a good time for a heart attack! In ...
(Date:12/7/2016)... ... December 07, 2016 , ... “The Road To Restoration”: ... trial, not a one hour a week showing of hands. “The Road To Restoration” ... begins, “Perhaps you are familiar with the brass ring that you could reach out ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 2016   Arena Pharmaceuticals, Inc. (NASDAQ: ... enrollment in the ralinepag phase 2 trial.  Ralinepag is ... pathway for the treatment of pulmonary arterial hypertension (PAH). ... "This marks an important step in the ... focus on our pipeline," said Amit Munshi , ...
(Date:12/7/2016)... Conn. , Dec. 7, 2016 According to ... in more than one-third (38%) of patients with non-small cell ... epidermal growth factor receptor (EGFR) genetic mutation status. The findings ... ( LBA ID #6067 #P3.02b ) at the ... Vienna, Austria . The survey results revealed ...
(Date:12/7/2016)... 7,2016  Based on its recent analysis ... & Sullivan recognizes Nemaura Pharma Limited with ... for Enabling Technology Leadership. Nemaura Pharma,s transdermal ... traditional drug delivery technologies, especially in delivering ... delivery technologies, Memspatch and Micropatch respectively, facilitate ...
Breaking Medicine Technology: